# Phase 1 Leukemia, Lymphocytic: 27 recruiting (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials in phase 1 for Leukemia, Lymphocytic, Chronic, B-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Leukemia, Lymphocytic, Chronic, B-Cell trials: 27 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/leukemia-lymphocytic-chronic-b-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2026 | NCT07891468 | huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers | University of Pennsylvania | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891468) |
| July 1, 2026 | NCT07679919 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | Luminary Therapeutics | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679919) |
| November 6, 2025 | NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225439) |
| June 13, 2025 | NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing... | City of Hope Medical Center | Phase 1 | Recruiting | Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020533) |
| May 20, 2025 | NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980116) |
| March 5, 2025 | NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory... | City of Hope Medical Center | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859008) |
| December 2, 2024 | NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | Mayo Clinic | Phase 1 | Recruiting | Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712810) |
| November 27, 2024 | NCT06708897 | A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies | Lomond Therapeutics Holdings, Inc. | Phase 1 | Recruiting | CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06708897) |
| July 30, 2024 | NCT06528301 | A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies | Umoja Biopharma | Phase 1 | Recruiting | Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06528301) |
| January 5, 2024 | NCT06191887 | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for... | Mayo Clinic | Phase 1 | Recruiting | B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06191887) |
| September 14, 2023 | NCT06037018 | Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies | CytoCares Inc | Phase 1 | Recruiting | Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06037018) |
| July 27, 2023 | NCT05963217 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+... | University Health Network, Toronto | Phase 1 | Recruiting | Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or... | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05963217) |
| July 13, 2023 | NCT05943496 | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic... | OHSU Knight Cancer Institute | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05943496) |
| March 22, 2023 | NCT05780034 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Accutar Biotechnology Inc | Phase 1 | Recruiting | Relapsed/Refractory B-cell Malignancies | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05780034) |
| November 2, 2022 | NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Carna Biosciences, Inc. | Phase 1 | Recruiting | B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05602363) |
| September 16, 2022 | NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | Schrödinger, Inc. | Phase 1 | Recruiting | Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma... | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05544019) |
| June 14, 2022 | NCT05418088 | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Sponsor not shown (see the record) | Phase 1 | Recruiting | Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic... | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05418088) |
| November 23, 2021 | NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Nurix Therapeutics, Inc. | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular... | 572 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05131022) |
| October 25, 2021 | NCT05091424 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in... | Hoffmann-La Roche | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 332 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05091424) |
| May 19, 2021 | NCT04892277 | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies | Mayo Clinic | Phase 1 | Recruiting | Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04892277) |
| April 2, 2021 | NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Nurix Therapeutics, Inc. | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell... | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04830137) |
| March 19, 2021 | NCT04807881 | Phase Ib Clinical Study of Keynatinib | Medolution Ltd. | Phase 1 | Recruiting | Lymphoma, B-Cell | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04807881) |
| February 25, 2021 | NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL... | Newave Pharmaceutical Inc | Phase 1 | Recruiting | Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04771572) |
| January 11, 2021 | NCT04704323 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | Catapult Therapeutics | Phase 1 | Recruiting | Lymphocytic Leukemia, Chronic, SLL | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04704323) |
| September 11, 2020 | NCT04545762 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 1 | Recruiting | Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04545762) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Mayo Clinic | 3 |
| Nurix Therapeutics, Inc. | 2 |
| City of Hope Medical Center | 2 |
| Umoja Biopharma | 1 |
| University Health Network, Toronto | 1 |
| Baylor College of Medicine | 1 |
| Newave Pharmaceutical Inc | 1 |
| Lomond Therapeutics Holdings, Inc. | 1 |
| Medolution Ltd. | 1 |
| Accutar Biotechnology Inc | 1 |
| Catapult Therapeutics | 1 |
| OHSU Knight Cancer Institute | 1 |
| CytoCares Inc | 1 |
| University of Pennsylvania | 1 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 1 |
| Imugene Limited | 1 |
| Schrödinger, Inc. | 1 |
| Luminary Therapeutics | 1 |
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 1 |
| Carna Biosciences, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| Spain | 5 |
| Poland | 4 |
| Australia | 3 |
| China | 3 |
| France | 3 |
| Italy | 3 |
| United Kingdom | 3 |
| Moldova | 2 |
| Ukraine | 2 |
| Canada | 1 |
| Germany | 1 |
| South Korea | 1 |
| Netherlands | 1 |
| Switzerland | 1 |
| Romania | 1 |
| Georgia | 1 |
| Greece | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
- [Nursing schools in the United States](https://specstream.ai/data/businesses/nursing-schools/united-states)
- [Pediatric dentistry practices in the United States](https://specstream.ai/data/businesses/pediatric-dentistry-practices/united-states)
- [Primary care clinics in the United States](https://specstream.ai/data/businesses/primary-care-clinics/united-states)
- [Rehabilitation centers in the United States](https://specstream.ai/data/businesses/rehabilitation-centers/united-states)
- [Sign makers in the United States](https://specstream.ai/data/businesses/sign-makers/united-states)
